Page last updated: 2024-09-04

vatalanib and quinazolines

vatalanib has been researched along with quinazolines in 21 studies

Compound Research Comparison

Studies (vatalanib)	Trials (vatalanib)	Recent Studies (post-2010) (vatalanib)	Studies (quinazolines)	Trials (quinazolines)	Recent Studies (post-2010) (quinazolines)
276	42	98	19,235	2,417	8,835

Protein Interaction Comparison

Protein	Taxonomy	vatalanib (IC50)	quinazolines (IC50)
Epidermal growth factor receptor	Homo sapiens (human)		0.027

Research

Studies (21)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	14 (66.67)	29.6817
2010's	7 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Rosen, LS	1
Shiotsu, Y	1
Marmé, D	1
Cavanaugh, SX; Hammond, LA; Thomas, CR	1
Herbst, RS; Onn, A; Sandler, A	1
Brandt, R; Hynes, NE; Littlewood, A; O'Reilly, T; Schnell, C; Sini, P; Wood, J; Wyder, L	1
Soff, G; Zakarija, A	1
Agarwala, SS; Tawbi, H	1
Borner, MM	1
Filov, VA; Gershanovich, ML; Imianitov, EN; Stukov, AN	1
Eng, C; Shalan, N	1
Kiselyov, AS; Milligan, D; Ouyang, X	1
Armand, JP; Mir, O; Ropert, S	1
Lee, CB; Socinski, MA	1
Greten, TF; Manns, MP; Plentz, RR	1
Batey, MA; de Brito, LR; Hall, AG; Irving, JA; Jackson, G; Leung, HY; Maitland, H; Newell, DR; Squires, MS; Zhao, Y	1
Tolcher, AW	1
Döme, B; Török, S	1
Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S	1
Adamczak, J; Chatterjee, S; Florin, A; Franz, T; Heukamp, LC; Hinze, Y; Neumaier, B; Schöttle, J; Siobal, M; Ullrich, RT; Wieczorek, C	1
Bondesson, M; Hans, C; Harris, PS; Hemmer, MJ; Kleinstreuer, N; Knudsen, TB; McCollum, CW; Merchant, FA; Olin, J; Padilla, S; Shah, S; Tal, TL; Wood, CE	1

Reviews

13 review(s) available for vatalanib and quinazolines

Article	Year
Inhibitors of the vascular endothelial growth factor receptor. Hematology/oncology clinics of North America, 2002, Volume: 16, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Design; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Enzyme Inhibitors; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Phthalazines; Piperidines; Pyridines; Pyrroles; Quinazolines; Recombinant Proteins; RNA, Catalytic; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors	2002
[Current screening for molecular target therapy of cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:12 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib	2003
Angiogenesis and lung cancer: prognostic and therapeutic implications. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, May-10, Volume: 23, Issue:14 Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Lung; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib	2005
Update on angiogenesis inhibitors. Current opinion in oncology, 2005, Volume: 17, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A	2005
[Molecular targets in colon cancer]. Therapeutische Umschau. Revue therapeutique, 2006, Volume: 63, Issue:4 Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolones; Receptors, Platelet-Derived Growth Factor; Receptors, Somatomedin; Signal Transduction; Sirolimus; Sunitinib	2006
[Problems in the current target therapy of malignancies]. Voprosy onkologii, 2005, Volume: 51, Issue:5 Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Azathioprine; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinazolines; Quinolones; Rituximab; Sesquiterpenes; Sesquiterpenes, Guaiane; Trastuzumab	2005
Biological agents versus chemotherapy in the treatment of colorectal cancer. Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:10 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Irinotecan; Phthalazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A	2006
[Oral drugs inhibiting the VEGF pathway]. Bulletin du cancer, 2007, Volume: 94 Spec No Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A	2007
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials. Reviews on recent clinical trials, 2007, Volume: 2, Issue:2 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome	2007
Molecular therapy of pancreatic cancer. Minerva endocrinologica, 2010, Volume: 35, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A	2010
The evolution of phase I trials in cancer medicine: a critical review of the last decade. Chinese journal of cancer, 2011, Volume: 30, Issue:12 Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Drug Delivery Systems; Gefitinib; Humans; Maximum Tolerated Dose; Molecular Targeted Therapy; Neoplasms; Phthalazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Quinazolines	2011
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors]. Magyar onkologia, 2012, Volume: 56, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib	2012
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects]. Magyar onkologia, 2012, Volume: 56, Issue:3 Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays	2012

Other Studies

8 other study(ies) available for vatalanib and quinazolines

Article	Year
Protein kinase inhibitors: novel tools in cancer therapy. Der Urologe. Ausg. A, 2004, Volume: 43 Suppl 3 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Transformation, Neoplastic; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Signal Transduction	2004
An image worth a thousand lives? Nature biotechnology, 2004, Volume: 22, Issue:6 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzoquinones; Bibenzyls; Diagnostic Imaging; Down-Regulation; ErbB Receptors; Gefitinib; Heterocyclic Compounds, 1-Ring; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Magnetic Resonance Imaging; Molecular Probe Techniques; Mutation; Neoplasms; Phthalazines; Physiological Phenomena; Positron-Emission Tomography; Protein Binding; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Rifabutin; Stilbenes; Tissue Distribution; Trastuzumab	2004
The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jun-15, Volume: 11, Issue:12 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Coculture Techniques; Drug Synergism; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; ErbB Receptors; Fluorescent Antibody Technique; Gefitinib; Humans; Immunoblotting; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Phthalazines; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Pyridines; Quinazolines; Transplantation, Heterologous; Vascular Endothelial Growth Factor A	2005
Targeted Therapies in Cancer - Fourth International Congress. Angiogenesis inhibition. IDrugs : the investigational drugs journal, 2005, Volume: 8, Issue:12 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Humans; Neoplasms; Neovascularization, Pathologic; Phthalazines; Pyridines; Quinazolines; Vascular Endothelial Growth Factor A	2005
Novel inhibitors of VEGF receptors-1 and -2 based on azole-5-carboxamide templates. Bioorganic & medicinal chemistry letters, 2007, Jul-01, Volume: 17, Issue:13 Topics: Adenosine Triphosphate; Amides; Azoles; Binding, Competitive; Caco-2 Cells; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Models, Chemical; Phthalazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2	2007
Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma. Leukemia research, 2011, Volume: 35, Issue:9 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Evaluation, Preclinical; Humans; Indoles; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Phthalazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sunitinib; Xenograft Model Antitumor Assays	2011
Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer. Cancer research, 2014, May-15, Volume: 74, Issue:10 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mass Spectrometry; Mice; Mice, Nude; Multimodal Imaging; Phthalazines; Piperidines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays	2014
Immediate and long-term consequences of vascular toxicity during zebrafish development. Reproductive toxicology (Elmsford, N.Y.), 2014, Volume: 48 Topics: Angiogenesis Inhibitors; Animals; Animals, Genetically Modified; Blood Vessels; Embryo, Nonmammalian; Embryonic Development; ErbB Receptors; Phthalazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Tyrphostins; Vascular Endothelial Growth Factor Receptor-2; Zebrafish	2014